Karo Bio and Zydus Cadila collaborate in inflammatory diseases treatment

Karo Bio will leverage its expertise in nuclear receptor drug discovery including structural biology, drug design and compound characterization. Zydus Cadila will carry out a focused drug discovery and development program, undertaking pre-clinical studies, filing of the investigational new drug application and performing human clinical trials. Both parties will equally share risk and rewards for the collaboration program.

Karo Bio and Zydus Cadila have now initiated an intensive research program aimed at discovering selectively acting glucocorticoids. The design of new selective compounds will be based on Karo Bio’s detailed knowledge about structural biology aspects of ligand-receptor interactions.

Pankaj Patel, chairman and managing director of Zydus Cadila, said: “By combining the strengths of Karo Bio and Zydus Cadila, we should be able to design and develop novel molecules, which would eventually replace currently available steroids for treatment of inflammatory disorders.”